B. Giroux

542 total citations
23 papers, 438 citations indexed

About

B. Giroux is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, B. Giroux has authored 23 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in B. Giroux's work include Cancer Treatment and Pharmacology (7 papers), Cancer therapeutics and mechanisms (7 papers) and Drug Transport and Resistance Mechanisms (4 papers). B. Giroux is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Cancer therapeutics and mechanisms (7 papers) and Drug Transport and Resistance Mechanisms (4 papers). B. Giroux collaborates with scholars based in France, Italy and Belgium. B. Giroux's co-authors include Giudicelli Jf, C Richer, Jean-Pierre Bizzari, J. Bérille, B. Gérard, A. Meulemans, D. Henzel, Jean-Michel Derlon, M Namer and David Khayat and has published in prestigious journals such as Cancer, Annals of Oncology and European Journal of Cancer.

In The Last Decade

B. Giroux

23 papers receiving 428 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. Giroux France	13	198	154	139	107	42	23	438
Pasquale Fiduccia Italy	13	180 0.9×	151 1.0×	158 1.1×	149 1.4×	14 0.3×	38	600
Antonin Schmitt France	15	274 1.4×	208 1.4×	118 0.8×	57 0.5×	10 0.2×	48	557
Daniel D. VonHoff United States	10	205 1.0×	366 2.4×	89 0.6×	13 0.1×	57 1.4×	13	654
H. Tada Japan	8	110 0.6×	135 0.9×	162 1.2×	28 0.3×	16 0.4×	14	839
Yi Ling Teo Singapore	9	262 1.3×	228 1.5×	130 0.9×	57 0.5×	33 0.8×	11	625
Zejia Yang United States	11	239 1.2×	450 2.9×	66 0.5×	25 0.2×	27 0.6×	16	740
Friederike Schmidt Germany	15	55 0.3×	233 1.5×	201 1.4×	45 0.4×	109 2.6×	26	636
G. Tartarelli Italy	9	151 0.8×	120 0.8×	136 1.0×	15 0.1×	40 1.0×	18	444
Martine Hubert France	12	184 0.9×	120 0.8×	80 0.6×	88 0.8×	25 0.6×	15	591
Gérard Sanderink France	11	412 2.1×	243 1.6×	102 0.7×	31 0.3×	174 4.1×	17	866

Countries citing papers authored by B. Giroux

Since Specialization

Citations

This map shows the geographic impact of B. Giroux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Giroux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Giroux more than expected).

Fields of papers citing papers by B. Giroux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Giroux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Giroux. The network helps show where B. Giroux may publish in the future.

Co-authorship network of co-authors of B. Giroux

This figure shows the co-authorship network connecting the top 25 collaborators of B. Giroux. A scholar is included among the top collaborators of B. Giroux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Giroux. B. Giroux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pivot, Xavier, Emmanuel Chamorey, Emmanuel Guardiola, et al.. (2003). Phase I and pharmacokinetic study of the association of capecitabine–cisplatin in head and neck cancer patients. Annals of Oncology. 14(10). 1578–1586. 41 indexed citations

Pivot, Xavier, Ahmad Awada, D Gedouin, et al.. (2003). Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer. Annals of Oncology. 14(3). 373–377. 8 indexed citations

Aouali, Nasséra, et al.. (2003). Enhanced cytotoxicity and nuclear accumulation of doxorubicin-loaded nanospheres in human breast cancer MCF7 cells expressing MRP1. International Journal of Oncology. 23(4). 1195–201. 12 indexed citations

Awada, Ahmad, Sylvie Giacchetti, B. Gérard, et al.. (2002). Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules. Annals of Oncology. 13(12). 1925–1934. 9 indexed citations

Boiardi, A., Antonio Silvani, Emilio Ciusani, et al.. (2001). Fotemustine Combined with Procarbazine in Recurrent Malignant Gliomas: A Phase I Study with Evaluation of Lymphocyte O6-alkylguanine–DNA Alkyltransferase Activity. Journal of Neuro-Oncology. 52(2). 149–156. 13 indexed citations

Merlin, Jean‐Louis, et al.. (2000). Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles. Cytometry. 41(1). 62–72. 17 indexed citations

Hartmann, J.T., Hans‐Joachim Schmoll, Carsten Bokemeyer, et al.. (1998). Phase I pharmacological study of intra-arterially infused fotemustine for colorectal liver metastases. European Journal of Cancer. 34(1). 87–91. 4 indexed citations

Stupp, Roger, Jean Bauer, Olivia Pagani, et al.. (1998). Ventricular arrhythmia and torsade de pointe: Dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Annals of Oncology. 9(11). 1233–1242. 21 indexed citations

Giroux, B., et al.. (1997). Hypothyroïdie centrale de découverte néonatale. Archives de Pédiatrie. 4(6). 542–546. 2 indexed citations

10.

Petit, Thierry, Christian Borel, Olivier Rixe, et al.. (1996). Complete remission seven years after treatment for metastatic malignant melanoma. Cancer. 77(5). 900–902. 15 indexed citations

11.

Bérille, J., P.-J. Souquet, R Riou, et al.. (1996). A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. European Journal of Cancer. 32(1). 69–71. 38 indexed citations

12.

Adenis, Antoine, P. Fumoleau, P Pouillart, et al.. (1995). Phase II study of a new vinca alkaloid derivative, S12363, in advanced breast cancer. Cancer Chemotherapy and Pharmacology. 35(6). 527–528. 4 indexed citations

13.

Rixe, Olivier, Christian Borel, D. Paraïso, et al.. (1995). Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma. Melanoma Research. 5(6). 419–424. 10 indexed citations

14.

Khayat, David, B. Giroux, J. Bérille, et al.. (1994). Fotemustine in the Treatment of Brain Primary Tumors and Metastases. Cancer Investigation. 12(4). 414–420. 56 indexed citations

15.

Tranchand, Brigitte, Catherine Lucas, Pierre Biron, et al.. (1993). Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas. Cancer Chemotherapy and Pharmacology. 32(1). 46–52. 6 indexed citations

16.

Frénay, Marc, et al.. (1991). Phase II study of fotemustine in recurrent supratentorial malignant gliomas. European Journal of Cancer and Clinical Oncology. 27(7). 852–856. 46 indexed citations

17.

Meulemans, A., et al.. (1991). Comparative Diffusion Study of Two Nitrosoureas: Carmustine and Fotemustine in Normal Rat Brain, Human and Rat Brain Biopsies. Chemotherapy. 37(2). 86–92. 25 indexed citations

18.

Meulemans, A., et al.. (1989). Permeability of two Nitrosoureas, Carmustine and Fotemustine in Rat Cortex. Chemotherapy. 35(5). 313–319. 23 indexed citations

19.

Berdeaux, Alain, et al.. (1984). Tissue extraction of amiodarone and N‐desethylamiodarone in man after a single oral dose.. British Journal of Clinical Pharmacology. 18(5). 759–763. 12 indexed citations

20.

Jf, Giudicelli, M Chaignon, C Richer, B. Giroux, & J Guédon. (1984). Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients.. British Journal of Clinical Pharmacology. 18(5). 749–758. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact